1. Main characteristics of studies included in the meta‐analysis.

First author	Year	Country	Year of follow‐up	Treatment arms		Number of patients		Response criteria	Menopausal status	Receptor status
				TOR	TAM	TOR	TAM
Gershanovich	1997	Russia, Latvia, Estonia	1987‐1992	60 or 240 mg/day	40 mg/day	314	149	WHO/ECOG	post‐	pos or un
Hayes	1995	US, South Africa, and 4 other countries	1988‐1991	60 or 200 mg/day	20 mg/day	433	215	WHO/ECOG	post‐ or peri‐	pos or un
Kaufmann	1993	Germany	NR	60 mg/day	30 mg/day	71	71	WHO/ECOG	post‐	pos or un
Milla‐Santos	2001	Spain	1996‐1999	60 mg/day	40 mg/day	106	111	WHO/ECOG	post‐	pos
Nomura	1993	Japan	NR	40 mg/day	20 mg/day	57	57	NR	NR	NR
Pyrhonen	1997	Finland, Sweden, Norway, Poland, Hungary and the Czech Republic	1986‐1992	60 mg/day	40 mg/day	214	201	WHO	post‐	pos or un
Stenbygaard	1993	Denmark	1987‐1989	240 mg/day	40 mg/day	31	31	WHO	post‐	pos or un

NR: not reported
Pos or un: positive or unknown
TAM: tamoxifen
TOR: toremifene